Electrochemical Immunoassay for Capturing Capsular Polysaccharide of Burkholderia pseudomallei: Early Onsite Detection of Melioidosis

IF 4 2区医学 Q2 CHEMISTRY, MEDICINAL ACS Infectious Diseases Pub Date : 2024-05-07 DOI:10.1021/acsinfecdis.4c00133

Sasya Madhurantakam, Jayanth Babu Karnam, Vikram Narayanan Dhamu, Santosh Seetaraman, Marcellene A. Gates-Hollingsworth, David P. AuCoin, Danielle V. Clark, Kevin L. Schully, Sriram Muthukumar* and Shalini Prasad*,

{"title":"Electrochemical Immunoassay for Capturing Capsular Polysaccharide of Burkholderia pseudomallei: Early Onsite Detection of Melioidosis","authors":"Sasya Madhurantakam, Jayanth Babu Karnam, Vikram Narayanan Dhamu, Santosh Seetaraman, Marcellene A. Gates-Hollingsworth, David P. AuCoin, Danielle V. Clark, Kevin L. Schully, Sriram Muthukumar* and Shalini Prasad*, ","doi":"10.1021/acsinfecdis.4c00133","DOIUrl":null,"url":null,"abstract":"<p >This study presented the detection and quantification of capsular polysaccharide (CPS) as a biomarker for the diagnosis of melioidosis. After successfully screening four monoclonal antibodies (mAbs) previously determined to bind CPS molecules, the team developed a portable electrochemical immunosensor based on antibody–antigen interactions. The biosensor was able to detect CPS with a wide detection range from 0.1pg/mL to 1 μg/mL. The developed biosensor achieved high sensitivity for the detection of CPS spiked into both urine and serum. The developed assay platform was successfully programmed into a Windows app, and the sensor performance was evaluated with different spiked concentrations. The rapid electro-analytical device (READ) sensor showed great unprecedented sensitivity for the detection of CPS molecules in both serum and urine, and results were cross-validated with ELISA methods.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00133","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

This study presented the detection and quantification of capsular polysaccharide (CPS) as a biomarker for the diagnosis of melioidosis. After successfully screening four monoclonal antibodies (mAbs) previously determined to bind CPS molecules, the team developed a portable electrochemical immunosensor based on antibody–antigen interactions. The biosensor was able to detect CPS with a wide detection range from 0.1pg/mL to 1 μg/mL. The developed biosensor achieved high sensitivity for the detection of CPS spiked into both urine and serum. The developed assay platform was successfully programmed into a Windows app, and the sensor performance was evaluated with different spiked concentrations. The rapid electro-analytical device (READ) sensor showed great unprecedented sensitivity for the detection of CPS molecules in both serum and urine, and results were cross-validated with ELISA methods.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于捕捉假马勒伯克霍尔德氏菌囊多糖的电化学免疫测定：早期现场检测 Melioidosis。

这项研究介绍了如何检测和定量胶囊多糖（CPS），将其作为诊断类鼻疽的生物标记物。在成功筛选了四种先前确定能与 CPS 分子结合的单克隆抗体（mAbs）后，研究小组开发了一种基于抗体-抗原相互作用的便携式电化学免疫传感器。该生物传感器能够检测 CPS，检测范围从 0.1pg/mL 到 1 μg/mL。所开发的生物传感器在检测尿液和血清中添加的 CPS 时具有很高的灵敏度。所开发的检测平台已成功编程到 Windows 应用程序中，并用不同的加标浓度对传感器性能进行了评估。快速电分析装置（READ）传感器在检测血清和尿液中的 CPS 分子方面表现出前所未有的高灵敏度，其结果与 ELISA 方法进行了交叉验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Infectious Diseases CHEMISTRY, MEDICINALINFECTIOUS DISEASES&nb-INFECTIOUS DISEASES

CiteScore

9.70

自引率

3.80%

发文量

213

期刊介绍： ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to: * Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials. * Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets. * Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance. * Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents. * Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota. * Small molecule vaccine adjuvants for infectious disease. * Viral and bacterial biochemistry and molecular biology.